🆕 UPDATED APRIL 2026

COVID-19 Vaccine Tracker

Track the latest COVID-19 vaccines for the 2025-2026 season. Updated formulations from Pfizer/BioNTech, Moderna, and Novavax targeting the LP.8.1 and JN.1 variants. All vaccines approved August 2025.

📅 2025-2026 Season Vaccines (Current)

All vaccines updated August 2025 to target circulating variants. Four options available for immunization this season:

Pfizer/BioNTech - Comirnaty (2025-2026)
FDA APPROVED
Target Variant: LP.8.1 (SARS-CoV-2 Omicron sublineage)
Approval Date: August 2025
Type: mRNA vaccine (30 µg dose)
Age Groups: Ages 5+ with risk factors, and all adults 65+
Dosing: • Ages 5-11: 0.3 mL (10 µg)
• Ages 12+: 0.3 mL (30 µg)
Efficacy: 4-fold increase in LP.8.1-neutralizing antibodies (Phase 3 data)
Manufacturer: Pfizer Inc. & BioNTech SE
Moderna - Spikevax (2025-2026)
FDA APPROVED
Target Variant: LP.8.1 (SARS-CoV-2 Omicron sublineage)
Approval Date: August 27, 2025
Type: mRNA vaccine
Age Groups: 6 months through 64 years with risk factors, and all adults 65+
Dosing: • Ages 6 months-11 years: 0.25 mL
• Ages 12+: 0.5 mL
Unique Feature: Youngest age approval - from 6 months old
Manufacturer: Moderna, Inc.
Moderna - mNexspike (2025-2026) ★ NEW PRODUCT
NEW - AUG 2025
Target Variant: LP.8.1 (SARS-CoV-2 Omicron sublineage)
Approval Date: August 27, 2025
Type: mRNA vaccine (alternative Moderna formulation)
Age Groups: Ages 12-64 with risk factors, and all adults 65+
Dosing: 0.2 mL (10 µg) - single-dose prefilled syringe
Recommended Interval: 3 months after last dose (minimum 2 months acceptable)
Unique Feature: Alternative mRNA option with convenient single-dose prefilled syringe
Manufacturer: Moderna, Inc.
Novavax - Nuvaxovid (2025-2026)
FDA APPROVED
Target Variant: JN.1 strain (SARS-CoV-2)
Approval Date: August 27, 2025
Type: Adjuvanted protein subunit vaccine (NOT mRNA)
Age Groups: Ages 12+ with risk factors, and all adults 65+
Dosing: 0.5 mL (5 µg rS protein + 50 µg Matrix-M adjuvant)
Unique Feature: ONLY protein-based, non-mRNA option for those preferring traditional vaccine technology
Adjuvant: Matrix-M (saponin-based, enhances immune response)
Manufacturer: Novavax, Inc. (partnered with Sanofi)

📋 CDC 2025-2026 Vaccination Guidance

⚠️ IMPORTANT POLICY SHIFT

The CDC has moved from universal recommendations to "shared clinical decision-making" for the 2025-2026 season.

Who Should Get Vaccinated (Strong Recommendation):

All Adults 65+: Recommended - One dose of 2025-2026 vaccine
High-Risk Individuals: Recommended - Ages 6 months-64 years with:
• Chronic lung disease (COPD, asthma)
• Heart disease
• Diabetes
• Weakened immune system
• Obesity (BMI ≥30)
• Pregnancy
• Kidney or liver disease
Healthy Adults <65: Individualized decision - Consult healthcare provider
Benefits most outweigh risks for those with underlying conditions
Immunocompromised: May receive additional doses (≥2 months apart) per provider recommendation

Children's Vaccination Schedule:

Ages 6 months-4 years: Only Moderna Spikevax approved (Pfizer-BioNTech no longer authorized for this age group)

Ages 5+: All four vaccines available based on age-specific approvals

Key Changes from Previous Years:

📊 Vaccine Platform Comparison

Last Updated: April 28, 2026

Next Update: When 2026-2027 formulations are announced (typically May-August 2026)

Information based on FDA approvals, CDC guidance, and manufacturer data as of April 2026